standard biotools inc. - LAB

LAB

Close Chg Chg %
1.25 0.03 2.40%

Closed Market

1.28

+0.03 (2.40%)

Volume: 1.08M

Last Updated:

Dec 31, 2025, 4:00 PM EDT

Company Overview: standard biotools inc. - LAB

LAB Key Data

Open

$1.25

Day Range

1.23 - 1.28

52 Week Range

0.92 - 2.14

Market Cap

$492.24M

Shares Outstanding

384.57M

Public Float

368.61M

Beta

1.26

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.34

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.45M

 

LAB Performance

1 Week
 
-7.25%
 
1 Month
 
-14.67%
 
3 Months
 
-4.48%
 
1 Year
 
-26.86%
 
5 Years
 
N/A
 

LAB Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About standard biotools inc. - LAB

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA.

LAB At a Glance

Standard BioTools, Inc.
50 Milk Street
Boston, Massachusetts 02109
Phone 1-650-266-6000 Revenue 174.43M
Industry Medical Specialties Net Income -138,885,000.00
Sector Health Technology 2024 Sales Growth 64.032%
Fiscal Year-end 12 / 2025 Employees 818
View SEC Filings

LAB Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.544
Price to Book Ratio 1.401
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -3.039
Enterprise Value to Sales 2.054
Total Debt to Enterprise Value 0.092

LAB Efficiency

Revenue/Employee 213,242.054
Income Per Employee -169,786.064
Receivables Turnover 5.19
Total Asset Turnover 0.373

LAB Liquidity

Current Ratio 5.704
Quick Ratio 5.086
Cash Ratio 4.445

LAB Profitability

Gross Margin 43.573
Operating Margin -77.255
Pretax Margin -79.293
Net Margin -79.621
Return on Assets -29.695
Return on Equity -43.749
Return on Total Capital -27.517
Return on Invested Capital -39.907

LAB Capital Structure

Total Debt to Total Equity 6.995
Total Debt to Total Capital 6.538
Total Debt to Total Assets 5.388
Long-Term Debt to Equity 5.675
Long-Term Debt to Total Capital 5.304
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Standard Biotools Inc. - LAB

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
130.58M 97.95M 106.34M 174.43M
Sales Growth
-5.47% -24.99% +8.57% +64.03%
Cost of Goods Sold (COGS) incl D&A
61.21M 60.90M 55.89M 98.43M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
16.07M 15.03M 15.18M 16.86M
Depreciation
3.37M 2.80M 3.40M 12.30M
Amortization of Intangibles
12.70M 12.23M 11.78M 4.56M
COGS Growth
+11.66% -0.51% -8.22% +76.11%
Gross Income
69.37M 37.05M 50.45M 76.01M
Gross Income Growth
-16.75% -46.59% +36.16% +50.66%
Gross Profit Margin
+53.13% +37.83% +47.44% +43.57%
2021 2022 2023 2024 5-year trend
SG&A Expense
136.83M 149.76M 113.49M 210.76M
Research & Development
37.94M 35.00M 25.95M 58.94M
Other SG&A
98.89M 114.76M 87.54M 151.83M
SGA Growth
+1.84% +9.45% -24.22% +85.71%
Other Operating Expense
- - - -
-
Unusual Expense
(7.13M) 77.30M 13.56M 40.48M
EBIT after Unusual Expense
(60.33M) (190.00M) (76.60M) (175.24M)
Non Operating Income/Expense
491.00K 1.41M 6.96M 40.24M
Non-Operating Interest Income
- - 291.00K 20.20M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
3.82M 4.33M 4.57M 3.32M
Interest Expense Growth
+7.03% +13.29% +5.45% -27.39%
Gross Interest Expense
3.82M 4.33M 4.57M 3.32M
Interest Capitalized
- - - -
-
Pretax Income
(63.66M) (192.93M) (74.20M) (138.31M)
Pretax Income Growth
-17.67% -203.06% +61.54% -86.39%
Pretax Margin
-48.75% -196.97% -69.78% -79.29%
Income Tax
(4.42M) (2.83M) 452.00K 573.00K
Income Tax - Current - Domestic
63.00K 87.00K 197.00K 233.00K
Income Tax - Current - Foreign
(167.00K) 405.00K 373.00K 103.00K
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
(4.32M) (3.32M) (118.00K) 237.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(59.24M) (190.10M) (74.66M) (138.88M)
Minority Interest Expense
- - - -
-
Net Income
(59.24M) (190.10M) (74.66M) (138.88M)
Net Income Growth
-11.73% -220.91% +60.73% -86.03%
Net Margin Growth
-45.36% -194.08% -70.21% -79.62%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(59.24M) (190.10M) (74.66M) (138.88M)
Preferred Dividends
- - - 46.01M
-
Net Income Available to Common
(59.24M) (190.10M) (74.66M) (184.90M)
EPS (Basic)
-0.7816 -2.4277 -0.9431 -0.5234
EPS (Basic) Growth
-6.21% -210.61% +61.15% +44.50%
Basic Shares Outstanding
75.79M 78.31M 79.16M 353.25M
EPS (Diluted)
-0.7816 -2.4277 -0.9431 -0.5234
EPS (Diluted) Growth
-6.21% -210.61% +61.15% +44.50%
Diluted Shares Outstanding
75.79M 78.31M 79.16M 353.25M
EBITDA
(51.39M) (97.68M) (47.86M) (117.90M)
EBITDA Growth
-55.28% -90.07% +51.00% -146.34%
EBITDA Margin
-39.36% -99.72% -45.01% -67.59%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 1.775
Number of Ratings 3 Current Quarters Estimate -0.033
FY Report Date 03 / 2026 Current Year's Estimate -0.117
Last Quarter’s Earnings -0.05 Median PE on CY Estimate N/A
Year Ago Earnings -0.207 Next Fiscal Year Estimate -0.097
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 2
Mean Estimate -0.03 -0.04 -0.12 -0.10
High Estimates -0.01 -0.01 -0.04 -0.05
Low Estimate -0.05 -0.06 -0.16 -0.14
Coefficient of Variance -62.45 -68.63 -57.07 -63.01

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Standard Biotools Inc. - LAB

Date Name Shares Transaction Value
Apr 9, 2025 Michael Egholm President & CEO; Director 2,832,518 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 9, 2025 Michael Egholm President & CEO; Director 2,774,842 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.07 per share 2,969,080.94
Apr 9, 2025 Michael Egholm President & CEO; Director 196,513 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 9, 2025 Hanjoon Alex Kim Chief Financial Officer 962,281 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 9, 2025 Hanjoon Alex Kim Chief Financial Officer 940,840 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.07 per share 1,006,698.80
Apr 9, 2025 Hanjoon Alex Kim Chief Financial Officer 70,183 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 25, 2025 Sean Mackay SVP & Chief Business Officer 881,667 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 25, 2025 Sean Mackay SVP & Chief Business Officer 422,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Standard Biotools Inc. in the News